Survie à 3 ans des patients traités pour mélanome métastatique par prembrolizumab (Keynote-001) et devenir des patients en réponse complète
Caroline Robert(Institut Gustave Roussy), Stephen Hodi(Dana-Farber Cancer Institute), Roxanna Dronca(Mayo Clinic), Omid Hamid(Cedars-Sinai Medical Center), Azlina Daud, Richard W. Joseph(Daiichi Sankyo (United States)), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Peter Hersey(The University of Sydney), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrés Ribas, X.N. Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anthony M. Joshua(St Vincent's Hospital Sydney), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tara C. Gangadhar(University of Pennsylvania), Hassane M. Zarour(University of Pittsburgh)
Cited by 0
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k